EPISODE · Feb 10, 2014 · 6 MIN
Single Agent Rituximab Active in Nodular Lymphocyte Predominant Hodgkin Lymphoma
from Journal of Clinical Oncology (JCO) Podcast
This podcast describes the recent experience of single agent rituximab as management for newly diagnosed and relapsed nodular lymphocyte predominant Hodgkin lymphoma. The podcast includes a summary of the trial and discussion of the implications of the findings that rituximab has activity in both the upfront and relapsed setting.
NOW PLAYING
Single Agent Rituximab Active in Nodular Lymphocyte Predominant Hodgkin Lymphoma
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m